Skip to main content
Equibles

CAPTRUST FINANCIAL ADVISORS

Position in FATE — Fate Therapeutics Inc

CIK 1512024 RALEIGH, NC
Back to FATE Full portfolio

Position in FATE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$198,752
+$148,496 QoQ
Shares Held
73,612
+75.8% QoQ
Ownership
0.061%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#61
of 156 holders
Holding Since
Mar 2021
12 quarters on record
Voting authority Sole 46% Shared 0% None 54%

Common Shares in FATE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CAPTRUST FINANCIAL ADVISORS holds $169,003,876 across 125 Biotechnology names. FATE ranks #68 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 REGN
Regeneron Pharmaceuticals, Inc.
 36,464 $22,736,762
2 RPRX
Royalty Pharma plc
 337,298 $18,912,298
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 35,471 $17,619,509
4 EXEL
Exelixis, Inc.
 303,042 $16,488,515
5 LGND
Ligand Pharmaceuticals Inc
 34,607 $10,938,926
6 HALO
Halozyme Therapeutics, Inc.
 125,946 $9,857,793
7 CELC
Celcuity Inc.
 71,445 $7,474,575
8 INCY
Incyte Corp
 50,301 $5,702,121

All Filings in FATE

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $198,752 73,612
2026-03-31 $50,256 41,880
2025-12-31 $25,023 25,534
2025-09-30 $24,556 19,489
2025-06-30 $21,956 19,604
2025-03-31 $12,978 16,429
2022-06-30 $11,745 474
2022-03-31 $348 9
2021-12-31 $2,925 50
2021-09-30 $1,481 25
2021-06-30 $5,467 63
2021-03-31 $6,183 75